Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
Type:
Grant
Filed:
January 19, 2012
Date of Patent:
February 16, 2016
Assignees:
Suzhou Sciscape Biomedicine Science & Technology Co. Ltd., Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China
Inventors:
Chenggang Zhang, Junhuai Li, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li
Abstract: The invention relates to a compound of formula I, and a preparation method and use thereof. The compound has a bacterial quorum-sensing regulatory effect, and can be used for prevention and/or treatment of a disease caused by a bacterial infection.
Type:
Application
Filed:
December 10, 2013
Publication date:
January 7, 2016
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A, China
Abstract: Disclosed is a use of the CUEDC2 protein in the preparation of diagnostic agents for prognostic determination of the endocrinology therapy for the breast cancer patients and for the diagnosis of tumor such as breast cancer and ovarian cancer. The diagnostic agent comprises an antibody against the CUEDC2 protein, wherein the antibody is a monoclonal or polyclonal antibody against the CUEDC2 protein. Provided is a kit or a composition for prognostic determination of endocrinology therapy for the breast cancer patients and for the diagnosis of tumors such as breast cancer and ovarian cancer. The kit or composition comprises an antibody against the CUEDC2 protein. Further disclosed is a use of the CUEDC2 gene or protein in preparation of drugs for treating tumors, that is, small molecular substances and specific antibodies that specifically inhibit the expression or activity of the CUEDC2 gene\protein are used as a therapeutic agent to restore the sensitivity of drug-resistant tumors to drug treatment.
Type:
Grant
Filed:
October 28, 2011
Date of Patent:
December 1, 2015
Assignee:
Biomedical Analysis Center of Academy of Military Medical Sciences
Inventors:
Xuemin Zhang, Tao Zhou, Xin Pan, Huiyan Li, Ailing Li
Abstract: The present invention relates to an acyclic nucleoside phosphonate derivative and medical uses thereof. Specifically, the present invention relates to an acyclic nucleoside phosphonate derivative of Formula I having strong potency against viruses, such as hepatitis B virus, and low cytotoxicity, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, wherein R1 is H or methyl; each R2 is independently —R3 or —OR3, each R3 is independently C1-C8 alkyl, C3-C8 cycloalkyl. The present invention further relates to a process for preparing the compounds of Formula I, a pharmaceutical composition comprising the compound, and the medical uses of the compound. The acyclic nucleoside phosphonate derivative of the present invention has activity against virus such as hepatitis B virus and good in vivo behavioral traits.
Type:
Grant
Filed:
June 21, 2010
Date of Patent:
November 17, 2015
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Bohua Zhong, Xinhua He, Yongguang Wang, He Liu
Abstract: A dropper of eye drops comprises an eye drops storage for storing eye drops, which has an opening at the top and an eye drop outlet at the bottom; an elastic seal assembly installed inside the eye drop storage and forming a space for storing the eye drops together with the eye drop outlet; a pressing device installed at the top of the eye drop storage and configured to press the elastic seal assembly so as to compress the space for storing the eye drops, such that the eye drops are dropped out of the eye drop outlet. The dropper of eye drops eye drops by means of pressing the pressing device, and thus can be operated simply and safely, time- and energy-saving, and avoid waste. In addition, the dropper of eye drops has a simple design in structure and is convenient for use.
Type:
Application
Filed:
May 24, 2013
Publication date:
October 8, 2015
Applicant:
Affiliated Hospital, China Academy of Military Medical Sciences
Abstract: The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.
Type:
Grant
Filed:
March 29, 2010
Date of Patent:
October 6, 2015
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China
Abstract: The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.
Type:
Grant
Filed:
May 10, 2013
Date of Patent:
September 22, 2015
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Song Li, Wu Zhong, Juan Liu, Kunlun He, Junhai Xiao, Xinbo Zhou
Abstract: The present invention relates to a thiazine amide derivative and a pharmaceutical use thereof, and particularly to a compound of formula I (in the formula, variables are as described in the specification), a pharmaceutically acceptable salt, solvate or hydrate thereof. The present invention further relates to a method for preparing the compound, a pharmaceutical composition containing the compound, and a method or use thereof for prevention or treatment of neurodegenerative diseases.
Type:
Application
Filed:
August 24, 2012
Publication date:
July 23, 2015
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Song Li, Junhai Xiao, Dan Han, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xinbo Zhou, Xingzhou Li, Xiaokui Wang, Dan Jiang, Wei Chen, Hongying Liu
Abstract: The present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, its preparation method, a pharmaceutical composition comprising the compound, and its use in manufacture of a medicament for treatment of a disease or disorder, wherein R1, R2, R5, R6, X, Y, Q, W, n1 and n2 are defined as those stated in the description.
Type:
Application
Filed:
May 30, 2013
Publication date:
May 21, 2015
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Abstract: The present invention relates to an oseltamivir phosphate granule and preparation method thereof. The said granule comprises 1.97-19.8 wt. % oseltamivir phosphate, 75.0-97.5 wt. % diluent, 0.1-5.0 wt. % binder, optionally 1.0-5.0 wt. % edible flavoring essence, sweetener and/or edible pigment. It is prepared by using 30-55 v/v % aqueous ethanol solution as moistening agent. The granules prepared by the formulation and method according to the present invention have good uniformity and stability and are water-soluble. The administration dosage of the granules can be conveniently selected based on the age and body weight of patients. The oseltamivir phosphate granule is suitable for administering to old people, children and flu gravis patients and those patients that swallow inconveniently or difficulty. The preparation of the granule is simple and low in production cost.
Type:
Grant
Filed:
August 11, 2006
Date of Patent:
May 19, 2015
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.
Type:
Application
Filed:
October 10, 2014
Publication date:
May 14, 2015
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China
Abstract: The present invention relates to the fields of immunology and molecular biology and related to a B7-1-PE40KDEL exotoxin fusion gene-based DNA vaccine and the use thereof. Specifically, the DNA vaccine contains a recombinant expression vector, and the vector contains exotoxin fusion gene B7-1-PE40KDEL, which is effectively ligated into selected eukaryotic expression vectors, such as pcDNA3.1/Zeo(+), pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG, pSVL, and adenovirus. The invention also relates to the exotoxin fusion gene B7-1-PE40KDEL, the encoded exotoxin fusion protein, a recombinant expression vector that contains the exotoxin fusion gene, and compositions that contain the recombinant expression vector. The DNA vaccine in this invention has a good effect on the treatment or prevention of allogeneic tissue/organ transplant rejection and hematopoietic stem cell transplantation rejection such as GVHD.
Type:
Grant
Filed:
September 20, 2011
Date of Patent:
May 12, 2015
Assignee:
Affiliated Hospital of Academy of Military Medical Sciences, PLA
Abstract: The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.
Type:
Application
Filed:
May 10, 2013
Publication date:
April 30, 2015
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Song Li, Wu Zhong, Juan Liu, Kunlun He, Junhai Xiao, Xinbo Zhou
Abstract: A sustained-release pharmaceutical composition of topiramate, which is free of binding agent. The sustained-release pharmaceutical composition of topiramate is a sustained-release pellet, comprising a blank pellet core, a drug layer, and a sustained-release coating layer.
Type:
Application
Filed:
March 7, 2013
Publication date:
April 9, 2015
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Song Li, Chunsheng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang
Abstract: Disclosed are 2-arylimidazo[1,2-a]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates, wherein R1, R2, R3 and R4 are defined as in the specification.
Type:
Grant
Filed:
June 9, 2011
Date of Patent:
March 17, 2015
Assignees:
Institute of Pharmacology, Toxicology Academy of Military Medical Sciences P.L.A., China
Abstract: The present invention provides a combination product, which comprises immediate release pellet of phentermine and sustained-release pellet of topiramate, wherein the pellet of topiramate includes: a) a blank pellet core; b) an active drug layer that contains topiramate and is free of binding agent, the layer being located on surface of the blank pellet core; c) a sustained-release coating layer containing ethyl cellulose and PVP K30, the sustained-release coating layer being located on external of the active drug layer. The present invention further discloses a method for preparing the combination product.
Type:
Application
Filed:
March 20, 2013
Publication date:
February 12, 2015
Applicant:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Song LI, Chunseng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang
Abstract: The present invention provides a polypeptide TF1 for inhibiting type-2 Shiga-toxin activity, an encoding gene for the same and use thereof. The present polypeptide is named TF1 (also known as P1); its amino acid sequence is shown in SEQ ID NO: 1 in the sequence list. The polypeptide P1 can be prepared into medicine for preventing and/or treating diseases caused by type-2 Shiga toxin or the pathogens which produce type-2 Shiga toxin.
Type:
Grant
Filed:
September 9, 2011
Date of Patent:
February 3, 2015
Assignee:
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, PR China
Inventors:
Hui Wang, Tao Li, Qin Wang, Wei Tu, Xiaojun Hou, Yuenan Liu, Jing Shi, Kun Cai
Abstract: The invention relates to 2-(4-Substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof. Specifically, the invention relates to compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description. The compounds of formula I of the invention are a type of anti-HIV active compounds having new backbone structure.
Type:
Grant
Filed:
September 28, 2009
Date of Patent:
January 13, 2015
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
Inventors:
Lan Xie, Xingtao Tian, Kuo-Hsiung Lee, Shibo Jiang, Hong Lu
Abstract: Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof. The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.
Type:
Grant
Filed:
April 8, 2011
Date of Patent:
December 30, 2014
Assignee:
Institue of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China
Abstract: Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.
Type:
Grant
Filed:
August 2, 2011
Date of Patent:
September 30, 2014
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China